Business
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative
About this update from Uniqure N.v.
[{"type":"text","content":"LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 16-20 in Los Angeles, California. “Our presentations at ASGCT highlight the innovative work of our uniQure research scientists in expanding our pipeline capabilities, as well as that of our CMC and Operations team with their industry-leading expertise in AAV gene therapy manufacturing,” stated Ricardo Dolmetsch, Ph.D., president of research and development at uniQure. “We are particularly excited to share our progress in developing a gene therapy approach to treating a form of ALS caused by mutant C9orf72.” Specific details on uniQure’s presentations taking place at ASGCT include: Title: AAV vector DNA carrying two concatenated miRNA stem-loops is highly homogenous and stable in GLP-grade AAV product (Abstract #110)Presenter: Chenxia He, Director, Gene Therapy Technology Innovation, uniQureOral Session Title: AAV Vectors - Product Development Manufacturing: Analytics & Stability StudiesDate and Time: Thursday, May 18, 1:45 – 2:00 p.m. PDT Title: Lowering of toxic dipeptide proteins and phenotype rescue in an ALS mouse model treated with AAV-miQURE® targeting the repeat expansion-containing C9orf72 transcripts (Abstract #165)Presenter: Vanessa Zancanella, Sr. Scientist Global Research, uniQureOral Session Title: Neurological Gene Therapies in Advanced Stages of Clinical TranslationDate and Time: Thursday, May 18, 3:45 – 4:00 p.m. PDT Title: The capsid race: multiplexed analysis and comparison of rationally engineered AAV CNS capsids in vivo (Abstract #448)Presenter: Leonard Khirug, Senior Director, Technology Innovation, uniQurePoster Session Date and Time: Wednesday, May 17, 12:00 p.m. PDT Title: Phase-appropriate viral clearance studies for AAV manufacturing process (Abstract #415)Presenter: Aidan Hawkins, Engineer III DSP, Drug Substance Development, uniQurePoster Session Date and Time: Wednesday, May 17, 12:00 p.m. PDT Title: Next-generation Rep-Cap Dual baculoviruses for AAV production in insect cells (Abstract #422)Presenter: Finny Varghese, Sr. Sc...